lunes, 30 de septiembre de 2013

Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat

full-text:
Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat

Guidelines and Recommendations

chess pieces with arrows pointing up
Ensuring the integrity of clinical practice guidelines: a tool for protecting patientsExternal Web Site Icon
Lenzer J, et al. BMJ. 2013 Sep 17;347:f5535.
Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat (DG10),External Web Site Icon NICE, Sep 20
Medications for risk reduction of primary breast cancer in women: U.S. Preventive Services Task Force recommendation statementExternal Web Site Icon, USPSTF, Sep 24
Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?External Web Site Icon
Genetics in Medicine 2013 Sep 26
Tuberous sclerosis complex diagnostic criteria update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus ConferenceExternal Web Site Icon
Northrup H, et al. Pediatric Neurology vol 49 iss 4 pg 243-254 2012 Oct
Testing of CYP2C19 variants and platelet reactivity for guiding antiplatelet treatment,External Web Site Icon AHRQ, Sep 25

No hay comentarios:

Publicar un comentario